(Q38373223)

2 September 2017

1 reference

title

Relaxin: a novel agent for the treatment of acute heart failure (English)

1 reference

acute decompensated heart failure

2 September 2017

0 references

0 references

1 reference

Suprat S Wilson

1

1 reference

2 September 2017

Syed I Ayaz

series ordinal

2

1 reference

2 September 2017

Phillip D Levy

series ordinal

3

1 reference

2 September 2017

language of work or name

English

0 references

publication date

10 March 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

35

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

315-327

1 reference

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study

2 September 2017

cites work

1 reference

The "heart disease and stroke statistics--2013 update" and the need for a national cardiovascular surveillance system

21 January 2018

1 reference

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

21 January 2018

1 reference

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF

21 January 2018

1 reference

Design of the RELAXin in acute heart failure study.

21 January 2018

1 reference

Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group

21 January 2018

1 reference

Cardiac effects of relaxin in rats

21 January 2018

1 reference

Cardiovascular effects of relaxin: from basic science to clinical therapy

21 January 2018

1 reference

Relaxin, a pleiotropic vasodilator for the treatment of heart failure.

21 January 2018

1 reference

The vascular actions of relaxin

21 January 2018

1 reference

Recombinant relaxin: a review of pharmacology and potential therapeutic use.

21 January 2018

1 reference

'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease

21 January 2018

1 reference

Relaxin: a new approach for the treatment of acute congestive heart failure

21 January 2018

1 reference

Relaxin family peptide receptors--from orphans to therapeutic targets.

21 January 2018

1 reference

Activation of orphan receptors by the hormone relaxin

21 January 2018

1 reference

Relaxin as a cardiovascular hormone: physiology, pathophysiology and therapeutic promises

21 January 2018

1 reference

Relaxin family peptides and their receptors

21 January 2018

1 reference

Relaxin family peptide receptor (RXFP1) coupling to G(alpha)i3 involves the C-terminal Arg752 and localization within membrane Raft Microdomains.

21 January 2018

1 reference

The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling.

21 January 2018

1 reference

Relaxin stimulates protein kinase C zeta translocation: requirement for cyclic adenosine 3',5'-monophosphate production

21 January 2018

1 reference

Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites

21 January 2018

1 reference

Relaxin activates the MAP kinase pathway in human endometrial stromal cells

21 January 2018

1 reference

Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans

21 January 2018

1 reference

Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture

21 January 2018

1 reference

Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.

21 January 2018

1 reference

Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo

21 January 2018

1 reference

Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2

21 January 2018

1 reference

Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease.

21 January 2018

1 reference

Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure

21 January 2018

1 reference

Effects of Endothelin-1 and Endothelin-1 Receptor Blockade on Cardiac Output, Aortic Pressure, and Pulse Wave Velocity in Humans

21 January 2018

1 reference

The disposition of a human relaxin (hRlx-2) in pregnant and nonpregnant rats

21 January 2018

1 reference

Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease

21 January 2018

1 reference

Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial.

21 January 2018

1 reference

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

21 January 2018

1 reference

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes

21 January 2018

1 reference

Effect of nesiritide in patients with acute decompensated heart failure

21 January 2018

1 reference

The lost decade of nesiritide

21 January 2018

1 reference

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials

21 January 2018

1 reference

Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure

21 January 2018

1 reference

Pathophysiologic targets in the early phase of acute heart failure syndromes

21 January 2018

1 reference

The role of the emergency department in acute heart failure clinical trials--enriching patient identification and enrollment

21 January 2018

1 reference

Divergent trends in survival and readmission following a hospitalization for heart failure in the Veterans Affairs health care system 2002 to 2006.

21 January 2018

1 reference

Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia

21 January 2018

1 reference

Evidence for local relaxin ligand-receptor expression and function in arteries.

21 January 2018

1 reference

Receptor-induced dilatation in the systemic and intrarenal adaptation to pregnancy in rats

21 January 2018

1 reference

Relaxin-induced changes in renal function and RXFP1 receptor expression in the female rat.

21 January 2018

1 reference

Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide

21 January 2018

1 reference

Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB.

21 January 2018

1 reference

Relaxin is a potent renal vasodilator in conscious rats

21 January 2018

1 reference

Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers.

21 January 2018

1 reference

Early Vasoactive Drugs Improve Heart Failure Outcomes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1548

1 reference

2 September 2017

1 reference